Focus DermatologiaCarlo Mazzatenta
Direttore Servizio di Dermatologia
Azienda USL Toscana Nord Ovest – Area di Lucca
Carlo.mazzatenta@uslnordovest.toscana.it
Pubblicato su Il Pediatra n.3-23, pagg. 38-41
Bibliografia
1) Mehta AB, Nadkarni NJ, Patil SP, et al. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):371-8.
2) Stacey SK and McEleney M Topical Corticosteroids: Choice and Application Am Fam Physician. 2021; 103(6):337-343.
3) Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995 Feb;162(2):123-6.
4) Nakamura M, Abrouk M, Zhu H, et al. Update on the Systemic Risks of Superpotent Topical Steroids. J Drugs Dermatol. 2017 Jul 1;16(7):643-648.
5) Lax SJ, Harvey J, Axon E et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356
6) Long CC, Finlay AY. The finger-tip unit–a new practical measure. Clin Exp Dermatol. 1991 Nov;16(6):444-7.
7) El-Batawy MM, Bosseila MA, Mashaly HM, et al Topical steroids VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009 May;54(2):76-87.
8) Devasenapathy N, Chu A, Wong M, et al. AAAAI/ACAAI Joint Task Force on Practice Parameters for Atopic Dermatitis Guideline Development Group. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023 Jan;7(1):13-25.
9) Dong Y, Yang Q, Guo B, et al. The effects of tacrolimus plus phototherapy in the treatment of vitiligo: a meta-analysis. Arch Dermatol Res. 2021 Aug;313(6):461-471.
10) Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021 Nov 26;6(1):402.
11) Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges. 2022 Jan;20(1):19-24.
12) Fardos MI, Singh R, Perche PO et al. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. Expert Rev Clin Immunol. 2022 Mar;18(3):221-231.
13) Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021 Oct;85(4):854-862.
